优化用于眼部递送的 CARs。
Optimizing CARs for ocular delivery.
机构信息
Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, CO, USA.
出版信息
Nat Cancer. 2020 Oct;1(10):939-940. doi: 10.1038/s43018-020-00127-y. Epub 2020 Oct 12.
Abstract
Effective methods for treating retinoblastoma while preserving vision are an unmet clinical need. Subretinal delivery of a hydrogel containing T cells that secrete the cytokine IL-15 and express a chimeric antigen receptor directed at the ganglioside protein GD2 completely controls retinoblastoma in immunocompromised mice, with no obvious damage to the surrounding retina.
摘要
治疗视网膜母细胞瘤同时保留视力的有效方法是未满足的临床需求。将含有分泌细胞因子 IL-15 的 T 细胞的水凝胶递送至视网膜下，可完全控制免疫功能低下的小鼠中的视网膜母细胞瘤，同时对周围视网膜没有明显损伤，该水凝胶表达一种针对神经节苷脂蛋白 GD2 的嵌合抗原受体。
相似文献
1
Optimizing CARs for ocular delivery.优化用于眼部递送的 CARs。
Nat Cancer. 2020 Oct;1(10):939-940. doi: 10.1038/s43018-020-00127-y. Epub 2020 Oct 12.
2
GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision.包被于可注射水凝胶中的 GD2 特异性 CAR T 细胞控制视网膜母细胞瘤并保留视力。
Nat Cancer. 2020 Oct;1(10):990-997. doi: 10.1038/s43018-020-00119-y. Epub 2020 Oct 12.
3
CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.CD171 和 GD2 特异性 CAR-T 细胞在临床前体外试验中强烈靶向视网膜母细胞瘤细胞。
BMC Cancer. 2019 Sep 9;19(1):895. doi: 10.1186/s12885-019-6131-1.
4
Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas with Local and Systemic Delivery of CAR T Cells.用 CAR T 细胞局部和全身递送靶向 GPC2 的眼内和中枢神经系统转移性视网膜母细胞瘤。
Clin Cancer Res. 2024 Aug 15;30(16):3578-3591. doi: 10.1158/1078-0432.CCR-24-0221.
5
Prospects of anti-GD2 immunotherapy for retinoblastoma.视网膜母细胞瘤抗GD2免疫疗法的前景
Front Immunol. 2024 Nov 15;15:1499700. doi: 10.3389/fimmu.2024.1499700. eCollection 2024.
6
Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 Breast Cancer Metastasis to the Brain.嵌合抗原受体修饰 T 细胞的区域性递送可有效靶向 HER2 阳性乳腺癌脑转移。
Clin Cancer Res. 2018 Jan 1;24(1):95-105. doi: 10.1158/1078-0432.CCR-17-2041. Epub 2017 Oct 23.
7
Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model.单次 CAR-T 细胞治疗可控制同种异体小鼠模型中的播散性卵巢癌。
J Immunother Cancer. 2023 May;11(5). doi: 10.1136/jitc-2022-006509.
8
Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors.41BB 和 CD28 通过共刺激嵌合抗原受体膜近端的平行定位实现协同性 T 细胞信号传导。
Cell Rep Med. 2021 Dec 21;2(12):100457. doi: 10.1016/j.xcrm.2021.100457.
9
Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma.嵌合抗原受体 T 细胞靶向 GD2 和 GPC2 增强高危神经母细胞瘤的抗肿瘤活性。
Cytotherapy. 2024 Nov;26(11):1308-1319. doi: 10.1016/j.jcyt.2024.05.023. Epub 2024 May 31.
10
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.嵌合抗原受体 T 细胞的临床前开发，该细胞具有抗原诱导的 IL18 执行功能，用于治疗 GD2 阳性实体瘤。
Clin Cancer Res. 2024 Aug 15;30(16):3564-3577. doi: 10.1158/1078-0432.CCR-23-3157.
引用本文的文献
1
Emerging New Therapeutics for Retinoblastoma.视网膜母细胞瘤的新型治疗方法
Ocul Oncol Pathol. 2022 Nov;8(3):149-155. doi: 10.1159/000524919. Epub 2022 May 9.
本文引用的文献
1
'Off-the-shelf' allogeneic CAR T cells: development and challenges.现成的异体嵌合抗原受体 T 细胞：开发与挑战。
Nat Rev Drug Discov. 2020 Mar;19(3):185-199. doi: 10.1038/s41573-019-0051-2. Epub 2020 Jan 3.
2
CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.CD171 和 GD2 特异性 CAR-T 细胞在临床前体外试验中强烈靶向视网膜母细胞瘤细胞。
BMC Cancer. 2019 Sep 9;19(1):895. doi: 10.1186/s12885-019-6131-1.
3
Evidence of Tumour Microenvironment and Stromal Cellular Components in Retinoblastoma.视网膜母细胞瘤中肿瘤微环境及基质细胞成分的证据
Ocul Oncol Pathol. 2019 Feb;5(2):85-93. doi: 10.1159/000488709. Epub 2018 Jul 17.
4
What's New in Intra-Arterial Chemotherapy for Retinoblastoma?视网膜母细胞瘤动脉内化疗的新进展有哪些？
Int Ophthalmol Clin. 2019 Spring;59(2):87-94. doi: 10.1097/IIO.0000000000000266.
5
Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.经优化的 GD2 特异性嵌合抗原受体和白细胞介素-15 转导 T 细胞根除神经母细胞瘤。
Clin Cancer Res. 2019 May 1;25(9):2915-2924. doi: 10.1158/1078-0432.CCR-18-1811. Epub 2019 Jan 7.
6
Immune Privilege and Eye-Derived T-Regulatory Cells.免疫特权与眼源 T 调节细胞
J Immunol Res. 2018 May 20;2018:1679197. doi: 10.1155/2018/1679197. eCollection 2018.
7
Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M diffuse midline gliomas.抗 GD2 CAR T 细胞在 H3-K27M 弥漫性中线脑胶质瘤中的强大抗肿瘤疗效。
Nat Med. 2018 May;24(5):572-579. doi: 10.1038/s41591-018-0006-x. Epub 2018 Apr 16.
8
Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.全反式维甲酸减少骨髓来源抑制细胞可提高肉瘤嵌合抗原受体治疗效果。
Cancer Immunol Res. 2016 Oct;4(10):869-880. doi: 10.1158/2326-6066.CIR-15-0230. Epub 2016 Aug 22.
9
GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade.GD2特异性嵌合抗原受体T细胞在遇到抗原后会经历强烈的激活和清除，但可通过程序性死亡蛋白1（PD-1）阻断来保护其免受激活诱导的细胞死亡。
Mol Ther. 2016 Jun;24(6):1135-1149. doi: 10.1038/mt.2016.63. Epub 2016 Mar 29.
10
HER2/ERBB2 immunoreactivity in human retinoblastoma.人视网膜母细胞瘤中的HER2/ERBB2免疫反应性
Tumour Biol. 2016 May;37(5):6135-42. doi: 10.1007/s13277-015-4475-y. Epub 2015 Nov 27.
Zotero 插件